| Dr Dale S Horne, MD, PHD | |
|
3113 Bellevue Ave Ste 4100, Cincinnati, OH 45219-3286 | |
| (513) 475-8990 | |
| (513) 475-8577 |
| Full Name | Dr Dale S Horne |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 34 Years |
| Location | 3113 Bellevue Ave Ste 4100, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023011707 | NPI | - | NPPES |
| 2643438 | Medicaid | OH | |
| 0760401 | Medicaid | KY | |
| 200147410 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 35-087428 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Chester Hospital | West chester, OH | Hospital |
| University Of Cincinnati Medical Center, Llc | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Cincinnati Physicians Company Llc | 2264344480 | 1339 |
News Archive
Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.
A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE-), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib.
Body fat distribution in the trunk is more important than body weight when it comes to cancer risk in postmenopausal women, according to a study presented at the ESMO 2017 Congress in Madrid.
A new study published in Public Health Nutrition examines the potential effects of Brexit on the 'Sugar Tax' and coronary heart disease in England.
› Verified 6 days ago
| Entity Name | University Of Cincinnati Physicians Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801840434 PECOS PAC ID: 2264344480 Enrollment ID: O20031105000123 |
News Archive
Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.
A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE-), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib.
Body fat distribution in the trunk is more important than body weight when it comes to cancer risk in postmenopausal women, according to a study presented at the ESMO 2017 Congress in Madrid.
A new study published in Public Health Nutrition examines the potential effects of Brexit on the 'Sugar Tax' and coronary heart disease in England.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dale S Horne, MD, PHD 3113 Bellevue Ave, Ste 4100, Cincinnati, OH 45219-3286 Ph: (513) 221-1100 | Dr Dale S Horne, MD, PHD 3113 Bellevue Ave Ste 4100, Cincinnati, OH 45219-3286 Ph: (513) 475-8990 |
News Archive
Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.
A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE-), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib.
Body fat distribution in the trunk is more important than body weight when it comes to cancer risk in postmenopausal women, according to a study presented at the ESMO 2017 Congress in Madrid.
A new study published in Public Health Nutrition examines the potential effects of Brexit on the 'Sugar Tax' and coronary heart disease in England.
› Verified 6 days ago
Daniel Barnes Webb, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3113 Bellevue Ave, Cincinnati, OH 45219 Phone: 513-475-8990 Fax: 513-475-8577 | |
Dr. Michael J Kramer, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 9250 Blue Ash Rd, Cincinnati, OH 45242 Phone: 513-792-7445 Fax: 513-792-7451 | |
Dr. Thomas S Berger, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 3825 Edwards Rd, Suite 300, Cincinnati, OH 45209 Phone: 513-221-1100 Fax: 513-569-5297 | |
Joseph Cheng, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 Piedmont Ave, Cincinnati, OH 45219 Phone: 513-558-1177 Fax: 513-475-7243 | |
Dr. Yannick Grenier, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 4805 Montgomery Rd Ste 210, Cincinnati, OH 45212 Phone: 513-791-8080 Fax: 513-791-8085 | |
Dr. Michael C Kachmann, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3825 Edwards Rd, Suite 300, Cincinnati, OH 45209 Phone: 513-221-1100 Fax: 513-569-5297 |